
Michael Allgäuer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9344954/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Seminars in Cancer Biology, 2022, 84, 129-143.	9.6	41
2	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 251-265.	4.2	22
3	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
4	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. Journal of Physical Education and Sports Management, 2022, , mcs.a006156.	1.2	5
5	<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types. Journal of Pathology: Clinical Research, 2022, 8, 371-382.	3.0	10
6	MCL1 as putative target in pancreatoblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 265-272.	2.8	3
7	Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1071-1094.	4.5	21
8	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncolmmunology, 2021, 10, 1860586.	4.6	40
9	KRAS / GNAS â€testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasoundâ€guided workup of suspected mucinous neoplasms of the pancreas. Genes Chromosomes and Cancer, 2021, 60, 489-497.	2.8	13
10	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 640048.	2.8	4
11	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	2.0	8
12	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
13	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
14	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	2.8	10
15	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology, 2020, 20, 425-432.	1.1	11
16	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer, 2020, 142, 114-119.	2.0	28
17	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	5.1	14
18	Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of miceÂbearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunology, Immunotherapy, 2019, 68, 1805-1817.	4.2	40

Michael Allgäer

#	Article	IF	CITATIONS
19	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
20	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	3.7	32
21	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
22	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	3.7	36
23	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
24	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
25	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. Pathology, 2019, 51, 362-368.	0.6	10
26	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	5.1	24
27	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
28	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
29	Case report: a rare cause of a hypervascular nodule in a noncirrhotic liver. Zeitschrift Fur Gastroenterologie, 2019, 57, 57-60.	0.5	4
30	Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells. Carcinogenesis, 2019, 40, 551-559.	2.8	32
31	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
32	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	2.8	14
33	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	2.8	152
34	Encountering "Dropped―Gallstones During Robotic-assisted Laparoscopic Radical Prostatectomy. Urology, 2017, 103, e11-e12.	1.0	1
35	Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. BMC Cancer, 2017, 17, 495.	2.6	10
36	Harvey Cushing Treated the First Known Patient With Carney Complex. Journal of the Endocrine Society, 2017, 1, 1312-1321.	0.2	9

Michael Allgäer

#	Article	IF	CITATIONS
37	β-Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by â€̃gastric adenocarcinoma and proximal polyposis of the stomach' (GAPPS). Journal of Clinical Pathology, 2016, 69, 826-833.	2.0	20
38	Mitochondrial function controls intestinal epithelial stemness and proliferation. Nature Communications, 2016, 7, 13171.	12.8	134
39	Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics and Metabolism, 2016, 118, 55-59.	1.1	4
40	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
41	Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Modern Pathology, 2015, 28, 1249-1264.	5.5	85
42	The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β-catenin by sequestering TCF4 to the nuclear membrane. Science Signaling, 2015, 8, ra90.	3.6	67
43	A Key Role for E-cadherin in Intestinal Homeostasis and Paneth Cell Maturation. PLoS ONE, 2010, 5, e14325.	2.5	171